Cyclophilin Inhibitors for Hepatitis C Therapy

Fernando E. Membreno, Jennifer C. Espinales, Eric J. Lawitz

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


This article highlights a unique time in the history of Hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure Hepatitis C is discussed.

Original languageEnglish (US)
Pages (from-to)129-139
Number of pages11
JournalClinics in Liver Disease
Issue number1
StatePublished - Feb 2013


  • Alisporivir
  • Cyclophilin
  • Cyclophilin inhibitors
  • Debio 025
  • Interferon-free
  • NIM 811
  • Non-interferon
  • SCY-635

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Cyclophilin Inhibitors for Hepatitis C Therapy'. Together they form a unique fingerprint.

Cite this